Abstract
Rabies is a zoonose affecting wild and domestic animals and transmitted to humans through bites or scratches, causing over 60,000 human deaths, annually. The disease results from the transmission of a neurotropic virus leading to invariably deadly encephalitis. The post-exposure prophylaxis consists of careful washing and disinfection of the wound, antibiotherapy and tetanus prophylaxis when needed. Furthermore, rabies vaccine and rabies immunoglobulin [RIG] administration should be applied according to the type of wound, and the animal involved, according to the WHO protocols that are regularly updated. Unfortunately it is sometimes difficult to obtain RIG in some countries due to their high cost, leading to suboptimal treatment and possible death. Also, observance can be weak, due to the number of repeated visits required with protocols [up to five visits over 28 days]. These limitations justify research on new vaccines which were not conclusive at the moment. New RIGs are under development, including a monoclonal antibody cocktail which is more promising in a near future. Finally, vaccination protocols are in the way of being shortened in given conditions. Further studies are needed to validate these new practices.
Keywords: Humans, post exposure prophylaxis, rabies immunoglobulin, rabies, recommendations, vaccines.
Infectious Disorders - Drug Targets
Title:Current Perspectives on Rabies Postexposure Prophylaxis
Volume: 15 Issue: 1
Author(s): Agathe Blaise and Philippe Gautret
Affiliation:
Keywords: Humans, post exposure prophylaxis, rabies immunoglobulin, rabies, recommendations, vaccines.
Abstract: Rabies is a zoonose affecting wild and domestic animals and transmitted to humans through bites or scratches, causing over 60,000 human deaths, annually. The disease results from the transmission of a neurotropic virus leading to invariably deadly encephalitis. The post-exposure prophylaxis consists of careful washing and disinfection of the wound, antibiotherapy and tetanus prophylaxis when needed. Furthermore, rabies vaccine and rabies immunoglobulin [RIG] administration should be applied according to the type of wound, and the animal involved, according to the WHO protocols that are regularly updated. Unfortunately it is sometimes difficult to obtain RIG in some countries due to their high cost, leading to suboptimal treatment and possible death. Also, observance can be weak, due to the number of repeated visits required with protocols [up to five visits over 28 days]. These limitations justify research on new vaccines which were not conclusive at the moment. New RIGs are under development, including a monoclonal antibody cocktail which is more promising in a near future. Finally, vaccination protocols are in the way of being shortened in given conditions. Further studies are needed to validate these new practices.
Export Options
About this article
Cite this article as:
Blaise Agathe and Gautret Philippe, Current Perspectives on Rabies Postexposure Prophylaxis, Infectious Disorders - Drug Targets 2015; 15 (1) . https://dx.doi.org/10.2174/1871526515666150320161630
DOI https://dx.doi.org/10.2174/1871526515666150320161630 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Progenitor Cell Types in HIV-1 Infection: Bioactivity and Emerging Targets for Treatment
Current HIV Research Inactivated- or Killed-Virus HIV/AIDS Vaccines
Current Drug Targets - Infectious Disorders Targeted Oncolytic Herpes Simplex Viruses for Aggressive Cancers
Current Pharmaceutical Biotechnology Recombinant Rhabdoviruses as Potential Vaccines for HIV-1 and Other Diseases
Current HIV Research Biosynthesis and Biological Activities of In Vitro Derived Solasodine Glycoalkaloids from <i>Solanum laciniatum</i>
The Natural Products Journal Infection, Infectious Agents and Vascular Disease
Reviews on Recent Clinical Trials The Use of the Inhibitory Receptors for Modulating the Immune Responses
Current Pharmaceutical Design Agonists of the Tissue-Protective Erythropoietin Receptor in the Treatment of Parkinson’s Disease
Current Topics in Medicinal Chemistry EDITORIAL
Current Signal Transduction Therapy Mosquito and Tick-borne Illnesses in the United States. Guidelines for the Recognition and Empiric Treatment of Zoonotic Diseases in the Wilderness.
Infectious Disorders - Drug Targets Oral Mucosal Immunization: Recent Advancement and Future Prospects
Current Immunology Reviews (Discontinued) Proteomics and Protein Analyses of Ovine and Caprine Body Fluids: Current Studies and Future Promises
Current Protein & Peptide Science Rationale of Hyperbaric Oxygenation in Cerebral Vascular Insult
Current Vascular Pharmacology A Systems Biology Perspective on Rational Design of Peptide Vaccine Against Virus Infections
Current Topics in Medicinal Chemistry HIV-1: The Confounding Variables of Virus Neutralization
Current Drug Targets - Infectious Disorders Validating Immunotherapy in Alzheimer’s Disease: The EB101 Vaccine
Current Pharmaceutical Design Future Targeted Disease Modifying Drugs for Alzheimer's Disease
Recent Patents on CNS Drug Discovery (Discontinued) Medicinal Plants with anti-Acanthamoeba Activity: A Systematic Review
Infectious Disorders - Drug Targets Dabigatran Reversal with Idarucizumab in an Emergency Lumbar Puncture: A Case Report
Current Drug Safety Melatonin in Bacterial and Viral Infections with Focus on Sepsis: A Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery